phenylalanine has been researched along with melflufen in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (28.57) | 24.3611 |
| 2020's | 20 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, KC; Chauhan, D; Lewensohn, R; Munshi, N; Paba-Prada, C; Ray, A; Richardson, P; Spira, J; Viktorsson, K | 1 |
| Dale, T; Fryknäs, M; Fuchs, PF; Gerwins, P; Gullbo, J; Larsson, R; Strese, S; Wickström, M | 1 |
| Alvfors, C; Berglund, Å; Gullbo, J; Hagberg, H; Harmenberg, J; Jerling, M; Lewensohn, R; Lisyanskaya, A; Nordström, E; Nygren, P; Orlov, S; Ringbom, M; Söderlind, K; Spira, J; Tholander, B; Ullén, A | 1 |
| Hååg, P; Holmsten, K; Juntti, T; Kanter, L; Lewensohn, R; Shah, CH; Sierakowiak, A; Spira, J; Tu, J; Ullén, A; Viktorsson, K; Zielinska-Chomej, K | 1 |
| Delforoush, M; Enblad, G; Gullbo, J; Larsson, R; Strese, S; Wickström, M | 1 |
| Anderson, KC; Chauhan, D; Das, DS; Gullbo, J; Nordström, E; Ravillah, D; Ray, A; Richardson, PG; Song, Y | 1 |
| Carlier, C; Ceelen, WP; De Vlieghere, E; Gullbo, J; Juntti, T; Larsson, R; Lewensohn, R; Nygren, P; Spira, J; Strese, S; Uustalu, M; Velander, E; Viktorsson, K | 1 |
| Gullbo, J; Haglund, C; Hassan, SB; Höglund, M; Larsson, R; Strese, S; Velander, E | 1 |
| Aschan, J; Pour, L; Robak, P; Schjesvold, F; Sonneveld, P | 1 |
| Anderson, K; Bringhen, S; Byrne, C; Chauhan, D; Harmenberg, J; Mellqvist, UH; Nordström, E; Paba-Prada, C; Palumbo, A; Plesner, T; Reeves, B; Richardson, PG; Sonneveld, P; Voorhees, P; Zubair, H | 1 |
| Asbjarnarson, A; Bergthorsson, JT; Gudjonsson, T; Ingthorsson, S; Joelsson, JP; Kricker, J; Lehmann, F; Nupponen, N; Schepsky, A; Slipicevic, A; Traustadottir, GA | 1 |
| Gullbo, J; Hajek, R; Hassoun, H; Larocca, A; Leleu, X; Oriol, A; Paner, A; Richardson, PG; Rodríguez-Otero, P; Schjesvold, FH | 1 |
| Alegre, A; Anderson, KC; Bakker, NA; Bladé, J; Byrne, C; Cavo, M; Harmenberg, J; Hassoun, H; Hiemenz, JW; Larocca, A; Laubach, JP; Leleu, X; Maisel, C; Mateos, MV; Mazumder, A; Moreb, JS; Nadeem, O; Oriol, A; Paner, A; Raptis, A; Richardson, PG; Rodriguez-Otero, P; Thuresson, M; Thuresson, S; Touzeau, C | 1 |
| Bringhen, S; Byrne, C; Harmenberg, J; Mellqvist, UH; Nordström, E; Obermüller, J; Plesner, T; Reeves, B; Richardson, PG; Sonneveld, P; Voorhees, PM | 1 |
| Hillengass, J; Holstein, SA; McCarthy, PL | 1 |
| Al-Janazreh, H; Canale, FA; Cutrona, G; D'Arrigo, G; Gentile, M; Martino, EA; Martino, M; Mendicino, F; Morabito, F; Morabito, L; Neri, A; Todoerti, K; Tripepi, G; Vigna, E | 1 |
| Lehmann, F; Lindberg, J; Nilvebrant, J; Nygren, PÅ | 1 |
| Banerjee, R; Goodman, A; Kelkar, AH; Midha, S; Mohyuddin, GR; Prasad, V | 1 |
| Jessee, JK | 1 |
| Gonsalves, WI; Kapoor, P | 1 |
| Alekseeva, Y; Bakker, NA; Byrne, C; Coriu, D; Delimpasi, S; Dimopoulos, MA; Doronin, V; Hájek, R; Harmenberg, J; Lazzaro, A; Legiec, W; Liberati, AM; Maisnar, V; Masszi, T; Mateos, MV; Mikala, G; Minarik, J; Moody, V; Pour, L; Richardson, PG; Robak, P; Rosiñol, L; Salogub, G; Schjesvold, FH; Sonneveld, P; Špička, I; Symeonidis, A; Thuresson, M | 1 |
| Bakker, NA; Schjesvold, FH; Sonneveld, P | 1 |
| Hadidi, SA | 1 |
| Emeh, P; Eskelinen, A; Gebraad, A; Heckman, CA; Kuismanen, K; Lehmann, F; Manninen, M; Miettinen, JJ; Miettinen, S; Nupponen, NN; Ohlsbom, R; Pakarinen, TK; Slipicevic, A | 1 |
| Dimopoulos, MA; Gay, F; Mateos, MV; Nadeem, O; Ocio, EM; Richardson, PG; Schjesvold, F; Touzeau, C | 1 |
| Efebera, YA; Larocca, A; Leleu, X; Mateos, MV; Nadeem, O; Paner, A; Richardson, PG; Rodríguez-Otero, P | 1 |
| Acs, K; Diao, Y; Färnegårdh, K; Färnegårdh, M; Fasth, KJ; Hammer, K; Lehmann, F; Svensson Gelius, S; Westermark, U | 1 |
| Cliff, ERS; Janakiram, M; Kesselheim, AS | 1 |
5 review(s) available for phenylalanine and melflufen
| Article | Year |
|---|---|
Melflufen for relapsed and refractory multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Multiple Myeloma; Phenylalanine; Recurrence; Survival Rate | 2020 |
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Melphalan; Multiple Myeloma; Phenylalanine | 2021 |
Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy.
Topics: Antineoplastic Agents; Cytotoxins; Drug Carriers; Drug Delivery Systems; Drug Design; Humans; Immunoconjugates; Melphalan; Neoplasms; Peptides; Pharmaceutical Preparations; Phenylalanine; Radiotherapy; Somatostatin | 2021 |
Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Melphalan; Multiple Myeloma; Peptides; Phenylalanine | 2022 |
Melphalan flufenamide for relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Multiple Myeloma; Phenylalanine | 2022 |
6 trial(s) available for phenylalanine and melflufen
| Article | Year |
|---|---|
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Alkylation; Antineoplastic Agents, Alkylating; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Male; Melphalan; Middle Aged; Neoplasms; Peptide Hydrolases; Phenylalanine; Prospective Studies | 2015 |
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Phenylalanine; Progression-Free Survival; Randomized Controlled Trials as Topic; Recurrence; Thalidomide | 2020 |
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Phenylalanine | 2020 |
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Europe; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Phenylalanine; Progression-Free Survival; Recurrence; Time Factors; United States | 2021 |
Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Phenylalanine; Survival Rate | 2021 |
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; COVID-19 Drug Treatment; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Phenylalanine; SARS-CoV-2; Thalidomide | 2022 |
17 other study(ies) available for phenylalanine and melflufen
| Article | Year |
|---|---|
In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Movement; Cell Survival; Disease Models, Animal; Drug Synergism; Female; Humans; Melphalan; Mice; Multiple Myeloma; Neovascularization, Pathologic; Phenylalanine; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo.
Topics: Alkylating Agents; Angiogenesis Inhibitors; Animals; Cattle; CD13 Antigens; Chick Embryo; Chorioallantoic Membrane; Drug Screening Assays, Antitumor; Human Umbilical Vein Endothelial Cells; Melphalan; Mice; Neovascularization, Pathologic; Phenylalanine; Prodrugs | 2013 |
Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Cell Line, Tumor; Dasatinib; Humans; Melphalan; Phenylalanine; Protein Kinase Inhibitors; src-Family Kinases; Urologic Neoplasms; Urothelium | 2016 |
In vitro and in vivo activity of melflufen (J1)in lymphoma.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; G2 Phase Cell Cycle Checkpoints; Humans; Lymphoma; Melphalan; Mice; Multiple Myeloma; Phenylalanine; Xenograft Model Antitumor Assays | 2016 |
A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Histones; Humans; Kinetics; Melphalan; Multiple Myeloma; Phenylalanine; Phosphorylation; Signal Transduction; Tumor Cells, Cultured | 2016 |
Preclinical activity of melflufen (J1) in ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytoreduction Surgical Procedures; Disease-Free Survival; Drug Evaluation, Preclinical; Female; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Melphalan; Mice; Mice, SCID; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylalanine; Xenograft Model Antitumor Assays | 2016 |
In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.
Topics: Animals; Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Synergism; Female; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Male; Melphalan; Mice, SCID; Middle Aged; Neoplastic Stem Cells; Phenylalanine; Time Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Melflufen, a peptide-conjugated alkylator, is an efficient anti-neo-plastic drug in breast cancer cell lines.
Topics: Animals; Antineoplastic Agents, Alkylating; Breast Neoplasms; CD13 Antigens; Cell Line, Tumor; Chick Embryo; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; DNA Damage; Female; Gene Expression Regulation, Neoplastic; Histones; Humans; Leucyl Aminopeptidase; Melphalan; Phenylalanine; Signal Transduction; Tumor Suppressor p53-Binding Protein 1 | 2020 |
Melflufen: A Next-Generation Nitrogen Mustard.
Topics: Animals; Antineoplastic Agents, Alkylating; Humans; Melphalan; Multiple Myeloma; Phenylalanine; Treatment Outcome | 2021 |
Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Biological Products; Clinical Trials as Topic; Drug Discovery; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Phenylalanine; Receptors, Antigen, T-Cell | 2022 |
Melflufen for multiple myeloma: a promise unfulfilled?
Topics: Humans; Melphalan; Multiple Myeloma; Phenylalanine | 2022 |
Melflufen in multiple myeloma: the conclusion matters - Authors' reply.
Topics: Humans; Melphalan; Multiple Myeloma; Phenylalanine | 2022 |
Melflufen in multiple myeloma: the conclusion matters.
Topics: Humans; Melphalan; Multiple Myeloma; Phenylalanine | 2022 |
Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen.
Topics: Bone Marrow; Bortezomib; Doxorubicin; Humans; Melphalan; Mesenchymal Stem Cells; Multiple Myeloma; Phenylalanine | 2022 |
Melflufen for the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Europe; Melphalan; Multiple Myeloma; Phenylalanine | 2022 |
A rapid intracellular enrichment of alkylating payload is essential for melphalan flufenamide potency and mechanism of action.
Topics: Antineoplastic Agents, Alkylating; Humans; Melphalan; Multiple Myeloma; Phenylalanine | 2023 |
Melflufen: post-hoc subgroup analyses and the US FDA Oncologic Drugs Advisory Committee.
Topics: Advisory Committees; Humans; Medical Oncology; Melphalan; Phenylalanine; United States | 2023 |